GlassScriptPhysician profile
Jolanta Brankiewicz
NPI 1629581525
$12,333.40
in general payments reported to CMS, 2019-2025
31 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,726 · 2022: $1,818 · 2023: $2,627 · 2024: $4,710 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,677 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,677.40 |
| Education | $111.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,196.74 | 2021-2025 | |
| Abbvie INC. | $1,701.12 | 2021-2025 | |
| Novo Nordisk INC | $1,689.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $875.49 | 2022-2025 | Watchman Flx, Watchman, Watchman Access System |
| Amarin Pharma, INC. | $846.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $475.95 | 2023-2025 | Airsupra, Breztri |
| Amgen INC. | $434.86 | 2023-2025 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $399.60 | 2021-2024 | Glassia |
| Glaxosmithkline, LLC. | $364.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $290.19 | 2024-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $278.99 | 2021-2025 | Belsomra, Steglatro, Lagevrio |
| Exact Sciences Corporation | $218.50 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $213.46 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $205.61 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Halozyme INC | $172.81 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $168.55 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.06 | 2024-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $115.84 | 2021 | |
| Idorsia Pharmaceuticals US INC | $71.36 | 2024 | Quviviq |
| Pfizer INC. | $70.32 | 2024 | |
| Sanofi-Aventis U.S. LLC | $69.84 | 2024-2025 | |
| Lundbeck LLC | $63.21 | 2024-2025 | Rexulti |
| Dexcom, INC. | $58.74 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $49.58 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $42.63 | 2024 | Jynarque, Rexulti |
| Currax Pharmaceuticals LLC | $28.83 | 2024 | Contrave |
| Viatris Specialty LLC | $23.46 | 2025 | Yupelri |
| Azurity Pharmaceuticals, INC. | $22.52 | 2025 | Azmiro |
| Inspire Medical Systems, INC. | $21.88 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $20.12 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $8.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolanta Brankiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.